David Beckham Launches Health Brand IM8 with Prenetics: Premium Wellness Products for Global Market

Prenetics and David Beckham Launch IM8 Health Brand

Hong Kong biotech start-up Prenetics has partnered with UK football star David Beckham to launch a new health and wellness brand called IM8. The brand aims to provide premium health products, starting with two offerings: Daily Ultimate Essentials and Daily Ultimate Longevity. These products will be available online and can be shipped to 31 countries, including Hong Kong, the US, the UK, and Singapore.

Beckham expressed pride in IM8, stating he uses the products and has experienced positive effects on his health. IM8 focuses on innovative health solutions, combining scientific knowledge with consumer needs. The Daily Ultimate Essentials product is a flavored powder that delivers 16 daily supplements for heart health and supports joints and muscles. The Daily Ultimate Longevity is a daily capsule that promotes cellular rejuvenation and healthy aging.

The global health supplement sector is growing rapidly, expected to rise from $167.5 billion in 2023 to $239.4 billion by 2028. This growth is driven by an aging population and increased health awareness following the Covid-19 pandemic. China’s health supplement market is also expanding, projected to reach $58.2 billion by 2027.

Prenetics has evolved from a genetic testing lab to a broader health service provider, including cancer screening. The company has expanded its presence outside of Hong Kong, with operations in the UK, Taiwan, Japan, and Southeast Asia. In 2022, Prenetics acquired Taiwan-based ACT Genomics to enhance its cancer diagnosis capabilities.

Danny Yeung, CEO of Prenetics, expressed excitement about IM8, highlighting the synergy between the brand’s mission and Beckham’s vision for health and wellness. Products will retail between $95 and $99, with discounts available through subscriptions.

This launch marks a significant step for Prenetics, which saw its net loss decrease to $64.8 million last year, down from $190.5 million in 2022, while revenue increased 65% to $21.7 million. The company’s success was bolstered during the pandemic, when it became a key provider of Covid-19 tests in Hong Kong.